Open Access LMU
metadata only
Minimum important slowing of disease progression as determined by the ALS functional rating scale – a survey of patient expectations toward disease-modifying drugs in ALS
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Amyotrophic Lateral Sclerosis: A Multicenter Retrospective Observational Registry#873107
- Impact of Physical Functioning on Patient-Reported Outcomes in ALS Patients at TidalHealth#1031314
- A Double-blind Randomised, Placebo-controlled Clinical Trial to Test Ambroxol Treatment in ALS#861035
- This Study Evaluates the Safety, Target Engagement, and Preliminary Efficacy of Galunisertib (TGF-βR1/ALK5 Inhibitor)Combined With Nerandomilast (PDE4 Inhibitor) in GREM2-positive ALS, a Biomarker-defined Subgroup Hypothesized to Reflect Heightened TGF-β/SMAD-driven Astrocytic and Fibrotic Signaling#867967
- Evaluation of Microglial Activation in ALS With [18F]PBR06 (Peripheral Benzodiazepine Receptor-06) PET#893659
Record · ID 215650
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive